Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

06 déc. 2023 07h00 HE | Source: Ractigen Therapeutics

Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01

This milestone marks Ractigen's transition into clinical development, with RAG-01 targeting NMIBC.
02 nov. 2023 08h00 HE | Source: Ractigen Therapeutics

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting
05 juin 2023 07h00 HE | Source: Ractigen Therapeutics

Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS

JIANGSU, China, June 05, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a biopharmaceutical company focused on the discovery, development, and commercialization of novel oligonucleotide...
03 mars 2023 09h00 HE | Source: Ractigen Therapeutics

Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

JIANGSU, China, March 03, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to RAG-17, a novel siRNA...
09 janv. 2023 07h00 HE | Source: Ractigen Therapeutics

Ractigen Therapeutics Announces the Appointment of Harri Järveläinen as Chief Operating Officer

SUZHOU, China, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, Inc. announced today that Dr. Harri Järveläinen has been appointed Chief Operating Officer of the Company. "I am thrilled to...